Skip to main content

Table 2 Clinical and demographic characteristics of the sample analyzed in the extension study of GSM treatment adherence during COVID-19 confinement

From: Women's knowledge about the genitourinary syndrome of menopause: adherence to its treatments in the COVID-19 era in a sample of them: COMEM-GSM study

  n (%) (n = 204)
Age  
Median (IQR*) 58 (54–60)
Years of menopause  
Median (IQR*) 50 (49–52)
Sexually active  
Yes 176 (86.3)
No 28 (13.7)
Level of education  
Basic-medium 112 (54.9)
University 92 (45.1)
Sexual activity during confinement  
Decrease 128 (62.7)
Stable 66 (32.3)
Increase 10 (4.9)
Indicated treatments  
Lubricants, moisturizers 48 (23.5)
Local estrogens 120 (58.8)
Prasterone 20 (9.8)
Ospemifene 12 (5.9)
MHT 4 (2)
Compliancea  
Do you ever forget to take your medication? 52 (25.5)
Do you take the medication at the prescribed times? 96 (47.1)
If you feel well, do you not take it? 52 (25.5)
If it makes you feel worse, do you not take it? 4 (2)
Good complianceb  
Yes 56 (27.5)
No 148 (72.5)
Reasons for poor compliance  
Omission 132 (66.7)
Changes in sexual activity 100 (49)
Fear of going out to purchase it 40 (19.6)
Price 36 (17.6)
Efficacy 20 (9.8)
Other 24 (11.8)
COVID infection  
Yes 24 (11.8)
No 180 (88.2)
  1. MTH Menopause hormone therapy
  2. *IQR: Interquartile range
  3. aQuestions included in the Morinsky–Green–Levine test [8]
  4. bCompliance was considered to be good if the 4 questions were answered as follows: No/Yes/No/No